Larotrectinib for treating advanced solid tumours with TRK fusions – final appraisal determination

DRAFT NICE guidance recommends Larotrectinib, for use within the CDF for NTRK fusion +ve solid tumours in adults and children if the disease is locally advanced or metastatic or surgery could cause severe health problems and they have no satisfactory treatment options.


National Institute for Health and Care Excellence